Le contenu

Treatment individualization joint GMP – SFPT (STP-PT) commission


The commission “treatment individualization” was created in March 2022, under the auspices of the GMP, in order to maintain and expand the dialogue initiated during the satellite session “Treatment individualization: improving interactions between industry and hospital”, jointly organized by Florence Gattacceca and Romain Guilhaumou, on behalf of the GMP and the STP-PT group (dedicated to Therapeutic Drug Monitoring) of the SFPT (French Society of Pharmacology and Therapeutics) on October 20, 2021 in Paris, just before the GMP 2021 annual meeting. 

The commission ambitions to develop interactions between industry and hospital, through R&D pharmacologists and their hospital counterparts, in the context of treatment individualization based on pharmacometrics. Indeed, the commission members believe that, despite some apparently contradictory needs and obligations, continuing the life of models from development to clinical practice will benefit both industry and hospital, and subsequently improve the patients’ outcome.


The commission meets on a quarterly basis. Points of contact for each therapeutic area will be established for both industry and hospital. The commission develops actions to increase awareness of actors (pharmaceutical companies, hospitals, software developers, drug agencies) about the benefits that could arise from more interactions on treatment individualization. The commission also supports the development of scientific collaborations between industry and hospital.